Business Description
Inovio Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US45773H2013
Compare
Compare
Traded in other countries / regions
INO.USAGBM.GermanyINO.Mexico0A43.UK IPO Date
2006-10-31Description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.81 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.09 | |||||
| Beneish M-Score | -3.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -59.5 | |||||
| 3-Year EBITDA Growth Rate | 20.2 | |||||
| 3-Year EPS without NRI Growth Rate | 7.7 | |||||
| 3-Year FCF Growth Rate | 26 | |||||
| 3-Year Book Growth Rate | -44.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.68 | |||||
| 9-Day RSI | 59.33 | |||||
| 14-Day RSI | 60.26 | |||||
| 6-1 Month Momentum % | 31.37 | |||||
| 12-1 Month Momentum % | -28.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | |||||
| Quick Ratio | 3.6 | |||||
| Cash Ratio | 3.41 | |||||
| Days Sales Outstanding | 463.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.5 | |||||
| Shareholder Yield % | -1.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -16036.9 | |||||
| Net Margin % | -16240.14 | |||||
| FCF Margin % | -14953.75 | |||||
| ROE % | -79.81 | |||||
| ROA % | -55.73 | |||||
| ROIC % | -242.41 | |||||
| ROC (Joel Greenblatt) % | -839.13 | |||||
| ROCE % | -72.61 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 280.27 | |||||
| PB Ratio | 2.01 | |||||
| Price-to-Tangible-Book | 2.01 | |||||
| EV-to-EBIT | -1.15 | |||||
| EV-to-EBITDA | -1.18 | |||||
| EV-to-Revenue | 184.58 | |||||
| EV-to-Forward-Revenue | 191.96 | |||||
| EV-to-FCF | -1.23 | |||||
| Price-to-Median-PS-Value | 9.09 | |||||
| Price-to-Net-Current-Asset-Value | 2.37 | |||||
| Price-to-Net-Cash | 2.58 | |||||
| Earnings Yield (Greenblatt) % | -86.96 | |||||
| FCF Yield % | -46.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inovio Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.774 | ||
| EPS (TTM) (€) | -5.658 | ||
| Beta | 1.78 | ||
| Volatility % | 55.43 | ||
| 14-Day RSI | 60.26 | ||
| 14-Day ATR (€) | 0.659793 | ||
| 20-Day SMA (€) | 8.0855 | ||
| 12-1 Month Momentum % | -28.91 | ||
| 52-Week Range (€) | 3.612 - 10.92 | ||
| Shares Outstanding (Mil) | 25.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inovio Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inovio Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inovio Pharmaceuticals Inc Frequently Asked Questions
What is Inovio Pharmaceuticals Inc(STU:GBM)'s stock price today?
The current price of STU:GBM is €9.82. The 52 week high of STU:GBM is €10.92 and 52 week low is €3.61.
When is next earnings date of Inovio Pharmaceuticals Inc(STU:GBM)?
The next earnings date of Inovio Pharmaceuticals Inc(STU:GBM) is 2024-05-10 Est..
Does Inovio Pharmaceuticals Inc(STU:GBM) pay dividends? If so, how much?
Inovio Pharmaceuticals Inc(STU:GBM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers